IDRX-42 (formerly M4205) is a highly selective small molecule KIT inhibitor compound developed for the treatment of gastrointestinal stromal tumors. The compound was originally discovered by the German company Merck and later out-licensed to IDRX.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.